Sri Lanka's medicines regulator, set up by the NMRA Act No. 5 of 2015. It registers medicines, approves clinical trials through its Clinical Trials Evaluation Committee, and sets maximum retail prices.
The National Medicines Regulatory Authority was established by the National Medicines Regulatory Authority Act, No. 5 of 2015, certified on 19 March 2015, which replaced the Cosmetics, Devices and Drugs Act, No. 27 of 1980. It describes itself as an independent authority in the Ministry of Health, governed by a board that has no involvement in regulatory decisions; those rest with the Chief Executive Officer, staff and expert committees. It regulates medicines, medical devices, borderline products, clinical trials, cosmetics and pharmacies, and the National Medicines Quality Assurance Laboratory works under it. Its office is in Colombo 2; the coordinates are approximate.
Its Guideline for the Conduct of Clinical Trials (GL-019, version 5, effective 15 October 2022) requires approval from the Clinical Trials Evaluation Committee and a recognised ethics review committee, screening of applications within 7 working days, and sets 75 days for processing a clinical trial application, excluding stop-clock, with a route for priority review where there is unmet medical need.
Under Gazette Extraordinary No. 2446/34 of 21 July 2025 and its pricing guideline (GL-033, version 1.1), the Authority sets a maximum retail price for each newly registered or renewed medicine as cost, insurance and freight plus duties and taxes plus a supply chain markup, checked against external and internal reference prices, and publishes the prices monthly.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/